LIPOCINE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.27 USD | -3.12% |
|
-9.29% | +88.89% |
| Apr. 12 | Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial | MT |
| Apr. 11 | Top Premarket Gainers | MT |
Financials (USD)
| Sales 2024 * | 2.03M | Sales 2025 * | - | Capitalization | 28.01M |
|---|---|---|---|---|---|
| Net income 2024 * | -12M | Net income 2025 * | - | EV / Sales 2024 * | 13.8 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.54
x | P/E ratio 2025 * |
-
| Employees | 17 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.96% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -3.13% | ||
| 1 week | -9.29% | ||
| Current month | +1.35% | ||
| 1 month | +23.71% | ||
| 3 months | +39.79% | ||
| 6 months | +103.47% | ||
| Current year | +88.89% |
1 week
4.68
5.67
1 month
3.807.15
Current year
2.767.15
1 year
2.317.15
3 years
2.3132.13
5 years
2.3158.65
10 years
2.31326.91
| Managers | Title | Age | Since |
|---|---|---|---|
Mahesh Patel
CEO | Chief Executive Officer | 67 | 96-12-31 |
Anthony DelConte
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Krista Fogarty
AUD | Comptroller/Controller/Auditor | 56 | 18-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Dana Ono
BRD | Director/Board Member | 71 | 14-01-05 |
Mahesh Patel
CEO | Chief Executive Officer | 67 | 96-12-31 |
John W. Higuchi
BRD | Director/Board Member | 56 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 5.27 | -3.13% | 11,286 |
| 24-04-18 | 5.44 | +2.26% | 21,350 |
| 24-04-17 | 5.32 | +11.76% | 34,899 |
| 24-04-16 | 4.76 | -11.11% | 37,039 |
| 24-04-15 | 5.355 | -7.83% | 95,973 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.27
USD
Average target price
33
USD
Spread / Average Target
+526.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +88.89% | 28.01M | |
| -3.10% | 102B | |
| +2.11% | 96.37B | |
| -1.80% | 21.37B | |
| -17.75% | 20.92B | |
| -6.91% | 18.64B | |
| -42.00% | 16.4B | |
| -28.19% | 13.53B | |
| +0.18% | 13.28B | |
| +19.90% | 10.85B |
- Stock Market
- Equities
- LPCN Stock
